ARS Pharmaceuticals, Inc. — Director's Dealing 2020

Dec 4, 2020

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Silverback Therapeutics, Inc. (SBTX)
CIK: 0001671858
Period of Report: 2020-12-03

Reporting Person: Piazza Jonathan (Chief Financial Officer)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock option (right to buy)	$10.25	2030-11-04	Common Stock (290582)		Direct

Footnotes

F1: 25% of the shares shall vest on November 5, 2021, and the remaining shares shall vest in 36 equal monthly installments.